Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002174 · ClinicalTrials.gov registry record · NA
Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients
A NA study, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00002174: Completed NA study, sponsored by Louisiana State University Health Sciences Center in New Orleans.
NCT00002174 is a NA study that has completed, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002174, a NA study, has completed, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
To determine if Thalidomide modulates the production of HIV-suppressor factors (MIP-1 alpha, MIP-1 beta, Rantes) and TH1 type cytokines (IL-12 and INF-gamma) in HIV-infected patients and alters viral load.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Phase | NA |
What the finished NCT00002174 record still lists
NCT00002174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00002174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002174 about?
NCT00002174 is a clinical study titled "Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients". To determine if Thalidomide modulates the production of HIV-suppressor factors (MIP-1 alpha, MIP-1 beta, Rantes) and TH1 type cytokines (IL-12 and INF-gamma) in HIV-infected patients and alters viral load.
What is the current status of trial NCT00002174?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants.
What interventions are being tested in trial NCT00002174?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00002174?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002174's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)